Marimed (MRMD) Equity Average (2011 - 2026)

Marimed (MRMD) has 16 years of Equity Average data on file, last reported at $48.3 million in Q1 2026.

• Equity Average for Q1 2026 came in at $48.3 million, down 17.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.3 million (down 17.06% YoY), and the FY2025 annual result was $54.3 million, down 14.81% from the prior year.
• Equity Average eased to $48.3 million in Q1 2026 per MRMD's latest filing, from $52.2 million in the prior quarter.
• Over five years, Equity Average peaked at $80.4 million in Q3 2023 and troughed at $39.9 million in Q1 2022.
• A 5-year average of $59.8 million and a median of $58.2 million in 2025 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2025: Equity Average soared 250.35% in 2022, then decreased 17.69% in 2025.
• A 5-year view of Equity Average shows it stood at $54.6 million in 2022, then soared by 36.23% to $74.4 million in 2023, then fell by 15.03% to $63.2 million in 2024, then dropped by 17.45% to $52.2 million in 2025, then declined by 7.48% to $48.3 million in 2026.
• Business Quant data shows MRMD's Equity Average at $48.3 million in Q1 2026, $52.2 million in Q4 2025, and $55.6 million in Q3 2025.